Sébastien Armanet

Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial.

Nicolas Servant, Anne Vincent-Salomon, Xavier Paoletti, 2015, The Lancet. Oncology.

PIK3CA Pathway Mutations Predictive of Poor Response Following Standard Radiochemotherapy ± Cetuximab in Cervical Cancer Patients

P. Petrow, I. Bièche, B. Weber, 2015, Clinical Cancer Research.

Human papilloma virus (HPV) integration signature in Cervical Cancer: identification of MACROD2 gene as HPV hot spot integration site

S. Rodenhuis, E. Barillot, A. Nicolas, 2020, British Journal of Cancer.

Abstract OT3-4-06: Circulating tumor cells to guide the choice between chemotherapy and hormone therapy as first line treatment for hormone receptors positive metastatic breast cancer patients: the STIC CTC METABREAST trial

B. Asselain, F. Bidard, J. Pierga, 2012 .

A randomized multicenter phase 3 trial of adjuvant fotemustine versus surveillance in high risk uveal melanoma (UM) patients (FOTEADJ).

V. Servois, L. Desjardins, B. Asselain, 2017 .

Designs and challenges for personalized medicine studies in oncology: focus on the SHIVA trial

A. Vincent-Salomon, T. Conroy, M. Stern, 2012, Targeted Oncology.

Abstract P2-02-17: T-DM1 in HER2-negative metastatic breast cancer patients with HER2-amplified circulating tumor cells: Current status of the CirCe T-DM1 phase II trial

M. Espié, M. Bollet, G. Romieu, 2016 .